Home

Ovarian cancer is fifth leading cause of cancer-related death in women and the deadliest of gynecologic cancers. In 2022, approximately 20,000 women will be diagnosed with ovarian cancer in the United States, and an estimated 12,800 will die from the disease. Worldwide, the annual death rate from ovarian cancer approaches 180,000 women.

The Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) was initiated in FY97 to support high-impact, cutting-edge research that fills unmet needs. The OCRP establishes priorities to target the most critical needs along the research development pipeline from basic to translational to clinical research, including clinical trials, and to push the field of ovarian cancer forward to our vision to “Eliminate ovarian cancer”.

IN 2018, the OCRP established the DOD Omics Consortium Award to supports a multi-institutional research effort conducted by leading ovarian cancer researchers and consumers that specifically focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer disease, with an emphasis on early detection and screening. The long-term goal of the Omics Consortium is to facilitate improvements in early detection and screening of ovarian cancer, although immediate benefits of the consortium will be in initial diagnosis and therapy.